Table 1 Clinicopathological characteristics of breast cancer patients in the study cohort

Surgical treatment

Lumpectomy

168 (63.1%)

113 (62.8%)

Mastectomy

84 (31.6%)

59 (32.8%)

Unknown

14 (5.3%)

8 (4.4%)

Age at diagnosis (years)

Median (Range - 30.6–89.8)

59.2

59.2

< 59

126 (47.4%)

88 (48.9%)

≥ 59

140 (52.6)

92 (51.1%)

Adjuvant treatment

Hormonal treatment

Tamoxifen

131 (49.2%)

94 (52.2%)

Aromatase Inhibitor

13 (4.9%)

8 (4.4%)

Chemotherapy

73 (2.7%)

66 (24.8%)

Radiotherapy

149 (56.0%)

101 (56.1%)

Therapy details not available

6 (2.2%)

6 (3.3%)

Tumor size (cm)

Mean ± SD

1.85 ± 1.525

1.82 ± 1.466

Minimum

0.1

0.1

Maximum

9

9

≤2 cm

198

81

>2 cm

57

96

Unknown

11

3

AJCC pTNM stage (n, %)

0 (DCIS + LCIS)

62 (23.3%)

-

I

94 (35.3%)

113(62.8%)

II

87 (32.7%)

58 (32.2%)

III

6 (2.3%)

5 (2.8%)

IV

17 (6.4%)

4 (2.2%)

Estrogen receptor (ER)

Negative

35 (13.1%)

33 (18.3%)

Positive

161 (60.6%)

136 (75.6%)

Unknown

70 (26.3%)

11 (6.1%)

Progesterone receptor (PR)

Negative

71(26.7%)

64 (35.6%)

Positive

123 (46.2%)

103 (57.2%)

Unknown

72 (27.1%)

13 (7.2%)

Grade

I

56 (21.1%)

42 (23.3%)

II

106 (39.8%)

66 (36.7%)

III

85 (32.0%)

65 (36.1%)

Unknown

19 (7.1%)

7 (3.9%)

Nodal status

Negative

204 (76.7%)

123 (68.3%)

Positive

62 (23.3%)

57 (31.7%)